Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Neoplasms 4Leukemia, Myeloid, Acute 3Carcinoma 3Small Cell Lung Carcinoma 1Sarcoma, Myeloid 1Myelodysplastic Syndromes 1Leukemia 1Hematologic Diseases 1Carcinoma, Small Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma 1Acute Disease 1

Interventions

Carboplatin 359Pemetrexed 275Cisplatin 229Paclitaxel 212Docetaxel 205Gemcitabine 160Erlotinib Hydrochloride 150Bevacizumab 132pembrolizumab 128Radiotherapy 112Nivolumab 88durvalumab 84Drug Therapy 84osimertinib 81atezolizumab 58Vinorelbine 53Gefitinib 53Radiosurgery 49Cetuximab 39Taxes 37130-nm albumin-bound paclitaxel 36Ipilimumab 34anlotinib 33Surgical Procedures, Operative 33Magnetic Resonance Spectroscopy 33Etoposide 30Albumin-Bound Paclitaxel 29tislelizumab 27icotinib 27Specimen Handling 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Non-Small-Cell Lung × vosaroxin × Clear all
NCT00252382 2018-09-24

Safety and Efficacy Clinical Study of SNS-595 for Second-Line Therapy in Patients With Advanced NSCLC

Sunesis Pharmaceuticals

Phase 2 Completed
31 enrolled 6 charts
Thoracic

Adenocarcinoma, Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡